Abstract
Background:The association between ABO blood group and the prognosis of hepatocellular carcinoma (HCC) remains unclear. We investigated the impact of ABO blood groups as a prognostic factor in HCC patients treated with transarterial chemoembolization (TACE). Materials and methods:We revisited records of all HCC patients who underwent TACE between January 2007 and December 2019 at a tertiary care hospital. The inclusion criteria were HCC patients, Child-Pugh score A5-B7, and treated with TACE monotherapy. The baseline characteristics of each patient were compared against their blood group and the survival analysis was carried out using Cox’s regression. With Bonferroni adjustment for multiple comparisons, P-values <.0125 were considered statistically significant. Results:Of 211 eligible patients, the frequencies of blood groups O, A, B, and AB were 89, 54, 56, and 12, respectively. Their respective months of median survival were 41, 20, 21, and 42. After adjustments in the six-and-twelve criteria and Child-Pugh scores, and using blood group O as the referent group, the coefficients (SE) of groups A, B, and AB were 0.69 (0.24), 0.47 (0.23), and 0.49 (0.49), respectively. A significant difference in survival was found only between patients with blood group O vs A (hazard ratio, 2.00; confidence interval, 1.25-3.21). Conclusions:ABO blood group is associated with the prognosis of HCC patients treated with TACE monotherapy. In our data, patients with blood group O tended to have the best survival. However, only blood group A patients had a significantly shorter survival rate comparing to blood group O.
Highlights
Hepatocellular carcinoma (HCC) is a commonly diagnosed malignancy worldwide and the fourth leading cause of tumor-related deaths after lung, breast, and stomach cancers (Bray et al, 2018)
We investigated the impact of ABO blood groups as a prognostic factor in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE)
ABO blood group is associated with the prognosis of HCC patients treated with TACE monotherapy
Summary
Hepatocellular carcinoma (HCC) is a commonly diagnosed malignancy worldwide and the fourth leading cause of tumor-related deaths after lung, breast, and stomach cancers (Bray et al, 2018). The median survival estimates of these unresectable HCC patients undergoing TACE is only 19.4 months (Lencioni et al, 2016). We investigated the impact of ABO blood groups as a prognostic factor in HCC patients treated with transarterial chemoembolization (TACE). The inclusion criteria were HCC patients, Child-Pugh score A5-B7, and treated with TACE monotherapy. Results: Of 211 eligible patients, the frequencies of blood groups O, A, B, and AB were 89, 54, 56, and 12, respectively. Their respective months of median survival were 41, 20, 21, and 42. Conclusions: ABO blood group is associated with the prognosis of HCC patients treated with TACE monotherapy. Only blood group A patients had a significantly shorter survival rate comparing to blood group O
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
